Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
New Phase III Study Of Avastin In Advanced Breast Cancer Meets Its Primary Endpoint Of Increasing The Time Patients Live
http://www.medicalnewstoday.com/articles/131155.php
Third study confirming the benefit of Avastin in breast cancer shows that Avastin can be effectively combined with commonly used chemotherapiesRoche announced that the Avastin study RIBBON-1 met its primary endpoint of increasing the time women with breast cancer lived without their disease advancing (known as progression-free survival) compared to chemotherapy alone, as determined by the treating physicians.
IU Simon Cancer Center Researchers' Breast Cancer Trials Offer Recognized Potential To Improve Treatment, Survival
http://www.medicalnewstoday.com/articles/131074.php
Two breast cancer clinical trials led by Indiana University Melvin and Bren Simon Cancer Center researchers are among 13 selected by a national panel as having the greatest potential to improve treatment and survival.
----------------------------------------------
** CANCER / ONCOLOGY News **
New Drug For Skin Cancer Approaching Commercialization
http://www.medicalnewstoday.com/articles/131152.php
A drug that is activated by light can be a quick, simple, and cheap treatment for tens of thousands of patients with skin cancer in Sweden alone. Researcher Leif Eriksson's team at rebro University in Sweden has now received about SEK 4 million from government research financiers, the Swedish Research Council and Vinnova, to further develop and commercialize the method.
Phase 3 Study Of Subcutaneous Relistor For Opioid-Induced Constipation For Chronic Non-Cancer Pain
http://www.medicalnewstoday.com/articles/131139.php
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that a phase 3 clinical study investigating RELISTOR® (methylnaltrexone bromide) subcutaneous injection to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain achieved statistical significance for the primary and key secondary efficacy endpoints.
NICE Approves Lung-Cancer Drug Provided Manufacturer Roche Offers Discounted Price For NHS, UK
http://www.medicalnewstoday.com/articles/131131.php
The National Institute for Health and Clinical Excellence (NICE) has recommended erlotinib, an epidermal growth factor receptor inhibitor, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) provided the manufacturer (Roche) supplies erlotinib at a discounted and equivalent price to docetaxel.
IU Simon Cancer Center Researchers' Breast Cancer Trials Offer Recognized Potential To Improve Treatment, Survival
http://www.medicalnewstoday.com/articles/131074.php
Two breast cancer clinical trials led by Indiana University Melvin and Bren Simon Cancer Center researchers are among 13 selected by a national panel as having the greatest potential to improve treatment and survival.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
NICE Approves Lung-Cancer Drug Provided Manufacturer Roche Offers Discounted Price For NHS, UK
http://www.medicalnewstoday.com/articles/131131.php
The National Institute for Health and Clinical Excellence (NICE) has recommended erlotinib, an epidermal growth factor receptor inhibitor, as an alternative to docetaxel as a second-line treatment option for patients with non-small-cell lung cancer (NSCLC) provided the manufacturer (Roche) supplies erlotinib at a discounted and equivalent price to docetaxel.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
St. Jude Identifies Genomic Causes Of A Certain Type Of Leukemia Relapse
http://www.medicalnewstoday.com/articles/131144.php
Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse. The finding offers a pathway to designing treatments for ALL relapse in children and, ultimately, in adults.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
No news for this category today.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment